Background
==========

Spinal muscular atrophy (SMA) is a common autosomal recessive hereditary disease characterized by degeneration of the anterior horn α-motor neurons in the spinal cord, leading to paralysis and atrophy of proximal muscles. The survival motor neuron (*SMN*) gene is the disease-causing gene of SMA \[[@B1]\], and it exists as two nearly identical copies, *SMN1*and *SMN2*. *SMN1*is the critical gene involved in SMA, as more than 90% of SMA patients have *SMN1*exon 7 homozygous deletions \[[@B1]-[@B3]\]. Homozygous absence of SMN2 genes does not cause SMA and is found in about 5% of normal individuals. In SMA patients, the number of *SMN2*copies is inversely correlated with disease severity \[[@B4]-[@B6]\]. Only five nucleotides differ between *SMN1*and *SMN2*. *SMN1*can be distinguished from *SMN2*by two nucleotide changes in exon 7 and 8, which can be used to detect the deletion of *SMN1*and establish the diagnosis of SMA. To date, four assays have been described for detecting the absence of *SMN1*: single-stranded conformation polymorphism (SSCP), restriction enzyme digestion analysis, denaturing high-performance liquid chromatography (DHPLC) analysis and liquid microbead arrays. SSCP is a very time-consuming procedure \[[@B1],[@B3]\]. Restriction enzyme digestion analysis is the traditional method for SMA, but its accuracy can be hindered by incomplete digestion \[[@B2]\]. DHPLC is a more recent technology for *SMN1*mutation screening \[[@B7]-[@B9]\], but it is confined to the WAVE Nucleic Acid Fragment Analysis System. While the liquid microbead arrays is a sensitive, high-throughput approach that can be used to detect *SMN1*exon 7 deletions from blood spots, the cost may prohibit its application in many laboratories \[[@B10]\].

High-resolution DNA melting analysis (HRMA) with saturation LC Green dyes is becoming a powerful post-PCR technique for genotyping and mutation scanning. Apparent advantages of HRMA include speed of analysis and convenience, as there is no need for processing or separation of PCR products. Recent reports indicate that the sensitivity and specificity is 100% for amplicons less than 400 bp, and those for amplicons between 400 to 1000 bp are 96.1% and 99.4%, respectively \[[@B11]\]. In this report, we present the results of a study using the HRMA method to analyze a cohort of SMA patients and controls. To date, there have been no reports using the HRMA method for the molecular analysis of SMA.

Methods
=======

Subjects
--------

A total of 55 unrelated patients with SMA and 46 unrelated normal individuals were recruited from April 2005 to April 2008. All of the patients fulfilled the diagnostic criteria \[[@B12]\] and were confirmed to have *SMN1*exon 7 homozygous deletions by RFLP and DHPLC analysis using the detailed procedure previously described \[[@B9],[@B13],[@B14]\]. Of the 46 normal controls analyzed by RFLP, 3 were homozygous for *SMN2*exon7 deletions. The remaining 43 normal controls possessed both *SMN1*and *SMN2*. Furthermore, 12 of the normal individuals were analyzed by real-time fluorescence quantitative PCR, as previously reported \[[@B6],[@B15]\]. Informed consent was obtained from each individual or parents of individuals younger than 18 years. The study was approved by the local ethics commission. Genomic DNA was isolated from peripheral blood lymphocytes using the QIAamp DNA Blood Minikit (QIAGEN, Hilden, Germany).

Asymmetric and symmetric PCR
----------------------------

The exon 7 and flanking area of the *SMN1*and *SMN2*genes were amplified by PCR, the primers were SMNF(5\'-AGACTATCAACTTAATTTCTGATCA-3\') and SMNR(5\'-GATTCACTTTCATAATGCTGG-3\'). The length of the PCR product was 241 base pair and contained 2 nucleotide differences between *SMN1*and *SMN2*. For asymmetric PCR, the 20 μL reaction contained 40 ng of genomic DNA, 200 μM dNTPs, 1.25 U Taq DNA polymerase (Dichuan Biosystem, China), 2.0 ul LCGreen Plus dye (Idaho Technology), 0.05 μM SMN F primer and 0.5 μM excess SMN R primer, and 0.5 μM unlabeled probe to *SMN1*. The sequence of the *SMN1*probe is 5\'-TATAGCTATCTATGTCTATATAGCTAT-P-3\', in which the underlined \"G\" is specific to *SMN1*and \"-P\" indicates a 3\' phosphate. For symmetric PCR, the reaction was similar to that of asymmetric PCR except that both the SMNF and SMNR primers were 0.5 μM, and the *SMN1*probe was absent. The PCR reactions were performed in a 9700 Thermal Cycler (Applied Biosystems, Foster City, CA); the conditions included an initial denaturation at 94°C for 2 min, followed by 45 cycles of 94°C for 30 s, 57°C for 30 s, and 72°C for 30 s and a final extension at 72°C for 5 minutes.

Melting curve acquisition and analysis
--------------------------------------

The PCR products were transferred to a 96-well plate and put on the LightScanner (Idaho Technology). The samples were first denatured at 95°C and rapidly cooled to 40°C at a rate of 20°C/s, then melted from 60°C to 95°C with a slope of 0.1°C/s. The data was acquired every 1°C for a total of 25 readings. Melting curves were analyzed with LightScanner software (Idaho Technology Inc).

Results
=======

HRMA with unlabeled probe
-------------------------

As illustrated in Figure [1A](#F1){ref-type="fig"}, HRMA displayed three types of melting curve shapes that correlated with the genotype of all the patients and controls. Samples from 55 SMA patients with a confirmed diagnosis of SMN1 exon 7 homozygous deletion had a lower melting temperature due to deletion of *SMN1*(only possessing *SMN2*), inducing the probe-target mismatch. The three individuals with *SMN2*deletion (only possessing *SMN1*) had a higher melting temperature, because PCR products were perfectly paired to the unlabeled probe. Melting curves of the control samples with *SMN1*and *SMN2*genes showed both duplexes. On the other hand, the results showed no correlation between the height or area of the curves and the copy number of the *SMN1*or *SMN2*gene as determined by real-time fluorescence quantitative PCR.

![**Results of HRMA with (A) or without (B) unlabeled probe**. a, normal individuals with *SMN2*deletion; b, SMA patients with *SMN1*deletion; c, normal controls without *SMN1*and *SMN2*deletion (*SMN1/SMN2*heteroduplexes).](1471-2350-10-45-1){#F1}

HRMA without probe
------------------

Melting curve profiles of HRMA without probes were available for 6 SMA patients with *SMN1*deletion, 3 individuals with *SMN2*deletion, and 6 normal controls without *SMN1*or *SMN2*deletion. It was easy to identify the controls with *SMN1*and *SMN2*genes according to the melting curve shape, while it was difficult to distinguish patients with a *SMN1*deletion from normal individuals with a *SMN2*deletion (Figure [1B](#F1){ref-type="fig"}).

Discussion
==========

As already reported, SSCP, restriction enzyme digestion analysis, DHPLC and liquid microbead arrays could be used in detecting the absence of *SMN1*; all of these methods have advantages and disadvantages. Previously, one study showed that HRMA was superior to DHPLC in mutation scanning \[[@B16]\]. In the present study, we performed HRMA with and without an unlabeled probe for the SMA patients and controls. The exon 7 and flanking area of *SMN*gene were amplified. There are 2 nucleotide differences between *SMN1*and *SMN2*within this 241 bp product, which correspond to position intron6(-45) (G = SMN1, A = SMN2) and another to exon 7(+6) (C = SMN1, T = SMN2) \[[@B17]\]. According to a previous report \[[@B18]\], the unlabeled probe was designed to target *SMN1*, contained the intron6 (-45) difference in the center and was phosphorylated at the 3\' end to prevent polymerase extension during amplification. Asymmetric PCR was applied to improve the rate of hybridization, and the primer ratio of 1:10 referred to in the previous report \[[@B18]\]. The symmetric PCR was performed routinely. Melting transitions were monitored in the presence of LCGreen I, a saturated dye originally designed to detect heteroduplexes \[[@B19]\]. The results showed three types of melting curve that correlate to the presumed genotype (*SMN1, SMN2, SMN1/SMN2*) were clearly separable on the chromatogram of HRMA with an unlabeled probe, and we succeeded in distinguishing the 55 SMA cases from the controls without any error. However, the results of the HRMA without the unlabeled probe were not as good as those with the probe, as it was difficult to distinguish patients with the *SMN1*deletion from normal individuals with the *SMN2*deletion.

HRMA with an unlabeled probe has many advantages in detecting the deletion of *SMN1*compared with SSCP, restriction enzyme digestion analysis, DHPLC and liquid microbead arrays. First, HRMA is sensitive and accurate: the 55 patients with *SMN1*exon 7 homozygous deletions were detected by HRMA with 100% sensitivity and specificity in accordance with a previous report using this technology \[[@B11]\]. Second, HRMA is easy and rapid to perform, with only four requirements: PCR, saturation LC Green dyes, unlabeled probe and melting instrumentation. Melting analysis can be finished within several minutes.

Conclusion
==========

HRMA with saturation LC Green dyes and an unlabeled probe seems to be a useful alternative strategy for the diagnosis of SMA. This study has provided \"proof of principle\" data indicating the utility and sensitivity of HRMA when applied to diagnostic testing for SMA. However, our findings should be replicated in a much larger sampling of SMA patients to assess the specificity and sensitivity.
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